IL146241A0 - VARIANTS OF TRAF2 WHICH ACT AS AN INHIBITOR OF TNF-ALPHA (TNF α) SIGNALING PATHWAY - Google Patents

VARIANTS OF TRAF2 WHICH ACT AS AN INHIBITOR OF TNF-ALPHA (TNF α) SIGNALING PATHWAY

Info

Publication number
IL146241A0
IL146241A0 IL14624100A IL14624100A IL146241A0 IL 146241 A0 IL146241 A0 IL 146241A0 IL 14624100 A IL14624100 A IL 14624100A IL 14624100 A IL14624100 A IL 14624100A IL 146241 A0 IL146241 A0 IL 146241A0
Authority
IL
Israel
Prior art keywords
tnf
traf2
variants
inhibitor
alpha
Prior art date
Application number
IL14624100A
Other languages
English (en)
Original Assignee
Aventis Pharm Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharm Prod Inc filed Critical Aventis Pharm Prod Inc
Publication of IL146241A0 publication Critical patent/IL146241A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
IL14624100A 1999-04-30 2000-04-06 VARIANTS OF TRAF2 WHICH ACT AS AN INHIBITOR OF TNF-ALPHA (TNF α) SIGNALING PATHWAY IL146241A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13194099P 1999-04-30 1999-04-30
PCT/US2000/009178 WO2000066737A1 (en) 1999-04-30 2000-04-06 VARIANTS OF TRAF2 WHICH ACT AS AN INHIBITOR OF TNF-ALPHA (TNF α) SIGNALING PATHWAY

Publications (1)

Publication Number Publication Date
IL146241A0 true IL146241A0 (en) 2002-07-25

Family

ID=22451697

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14624100A IL146241A0 (en) 1999-04-30 2000-04-06 VARIANTS OF TRAF2 WHICH ACT AS AN INHIBITOR OF TNF-ALPHA (TNF α) SIGNALING PATHWAY

Country Status (10)

Country Link
EP (1) EP1180140A4 (zh)
JP (1) JP2002542826A (zh)
KR (1) KR20020012194A (zh)
CN (1) CN1309830C (zh)
AU (2) AU4076800A (zh)
CA (1) CA2372803A1 (zh)
HU (1) HUP0200946A3 (zh)
IL (1) IL146241A0 (zh)
MX (1) MXPA01011107A (zh)
WO (1) WO2000066737A1 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0003458D0 (en) * 2000-02-16 2000-04-05 Secr Defence Brit Rubber structure & method of making the same
WO2002098458A1 (en) * 2001-06-07 2002-12-12 Medvet Science Pty Ltd Sphingosine kinase interacts with traf2 and modulates tumor necrosis factor-induced cellular activity
US20050095246A1 (en) * 2003-10-24 2005-05-05 Medtronic, Inc. Techniques to treat neurological disorders by attenuating the production of pro-inflammatory mediators
WO2022152856A1 (en) * 2021-01-15 2022-07-21 Fundació Hospital Universitari Vall D'hebron - Institut De Recerca Methods and compositions for treating ischaemia in a subject
CN114672550B (zh) * 2022-05-05 2023-11-17 青岛大学 一种动脉粥样硬化生物标志物及其抑制剂和应用

Also Published As

Publication number Publication date
KR20020012194A (ko) 2002-02-15
CN1309830C (zh) 2007-04-11
EP1180140A4 (en) 2004-08-25
EP1180140A1 (en) 2002-02-20
JP2002542826A (ja) 2002-12-17
CN1353754A (zh) 2002-06-12
AU2005203749A1 (en) 2005-09-15
HUP0200946A3 (en) 2005-06-28
CA2372803A1 (en) 2000-11-09
HUP0200946A2 (hu) 2002-07-29
WO2000066737A9 (en) 2002-08-29
MXPA01011107A (es) 2002-08-09
AU4076800A (en) 2000-11-17
WO2000066737A1 (en) 2000-11-09

Similar Documents

Publication Publication Date Title
IL145778A0 (en) Methods and compositions for inhibiting the function of polynucleotide sequences
EP1406875A4 (en) N-HETEROCYCLIC INHIBITORS OF TNF-ALPHA EXPRESSION
IL166280A0 (en) Treatment of TNF? related disorders
IL149118A0 (en) Inhibitors of neuraminidases
EP1087770A4 (en) INHIBITORS OF PRENYL PROTEIN TRANSFERASE
EP1165084A4 (en) PRENYL PROTEIN TRANSFERASES INHIBITORS
EP1165082A4 (en) PRENYLE PROTEIN TRANSFERASE INHIBITORS
PL356422A1 (en) Tnf-alpha inhibitors
HK1038879A1 (en) Stabilization of compositions containing ace inhibitors using magnesium oxide
GB9930659D0 (en) Inhibitors of complement activation
AU5969101A (en) Modulators of tnf-alpha signaling
GB9923866D0 (en) Correlation of signalling messages
IL146241A0 (en) VARIANTS OF TRAF2 WHICH ACT AS AN INHIBITOR OF TNF-ALPHA (TNF α) SIGNALING PATHWAY
HUP0102363A3 (en) Treatment of follicular lymphomas using inhibitors of the lymphotoxin (lt) pathway
EP1158982A4 (en) Prenyl protein transferase inhibitors
PT1090664E (pt) Dispositivo de descarga de lamas flutuantes
HUP0102259A3 (en) Methods of inhibiting corrosion using isomers of chloro-methylbenzotriazole
EP1221963A4 (en) METHODS OF INHIBITING OSTEOCLASTOGENESIS
EP1165013A4 (en) PRENYL PROTEIN TRANSFERASE INHIBITORS
EP1409463A4 (en) N-HETEROCYCLIC INHIBITORS OF TNF-ALPHA EXPRESSION
AU2003299137A8 (en) Inhibition of metallo-beta-lactamase
AU2003271988A8 (en) Modulation of tgfbeta-like signalling pathways
EP1158983A4 (en) Prenyl protein transferase inhibitors
AU8281398A (en) Methods of inhibiting or enhancing the tgfbeta-smad signaling pathway
AU2001232734A1 (en) Compositions containing potential spla2 inhibitors for the treatment of pain